ABL Bio Inc. (KOSDAQ:298380)
South Korea
· Delayed Price · Currency is KRW 190,600
-10,400 (-5.17%)
At close: Dec 5, 2025
ABL Bio Company Description
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.
Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea.
ABL Bio Inc.
| Country | South Korea |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Sang Hoon Lee |
Contact Details
Address: 456 Bongeunsa-ro Seoul, 13488 South Korea | |
| Phone | 82 2 3456 7300 |
| Website | ablbio.com |
Stock Details
| Ticker Symbol | 298380 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7298380007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sang Hoon Lee | Chief Executive Officer |
| Jaecheon Lee | Chief Financial Officer |
| Jung Dae Kim | Chief Operating Officer |